Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
Int Clin Psychopharmacol 2014 Jan;29(1):16-25
aDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Dresden, Germany bDepartment of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium cAlpine Clinic, Lafayette, Illinois dDepartment of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania eDepartment of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA fFormer AstraZeneca R&D, Södertälje, Sweden gFormer AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.

Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.
J Affect Disord 2013 Sep 14;150(2):639-43. Epub 2013 Mar 14.
Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder.
Psychopharmacol Bull 2012 Feb;45(1):5-30
Dr. Wang, MD, PhD, Beijing Anding Hospital, Capital Medical University, Xicheng District, Beijing, China. Dr. McIntyre, FRCPC, Department of Psychiatry, Penticton Regional Hospital, Penticton, British Columbia, Canada. Dr. Earley, MD, Mr. Raines, MS, AstraZeneca Pharmaceuticals, Wilmington, DE. Dr. Eriksson, MD, PhD, MBA, AstraZeneca R&D, Södertälje, Sweden.

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
J Clin Psychiatry 2009 Apr 7;70(4):540-9. Epub 2009 Apr 7.
Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.